Ryght, an innovative company specializing in generative AI (GenAI) technology for life science organizations, has officially launched its new platform, also called Ryght. This enterprise-grade platform is designed to enable companies to develop and deploy their own GenAI applications securely and privately. By leveraging industry-specific knowledge from biomedical literature and an expansive medical records database, Ryght aims to accelerate scientific research, clinical operations, and commercialization, ultimately providing actionable knowledge and informed decision-making for life science companies.
Traditionally, many companies have relied on their internal development teams to experiment with building GenAI applications. However, this approach can be costly, amounting to over $2 million per year, excluding labor costs and the diversion of resources from critical projects. For smaller companies, these expenses and time-consuming projects are often unattainable. Recognizing this gap, Ryght offers life science organizations an affordable and adaptable solution by incorporating GenAI into everyday tasks, expediting workflows, and streamlining operations.
Simon Arkell, CEO of Ryght, highlights that the platform is enterprise-grade, secure, and easy to deploy across life science companies of all sizes. It allows companies to safely query their own data and documents in various common formats. Additionally, Ryght’s team collaborates closely with companies to build and install individualized applications that seamlessly integrate with their specific data streams and industry needs. This partnership aims to provide more room for innovation within the life science industry by freeing up time and resources.
In an exciting development, BEK Health and Ryght have joined forces to co-develop applications that will incorporate Ryght’s GenAI capabilities into BEKHealth’s AI-powered patient-matching software platform. Dave Levin, CEO of BEKHealth, expresses enthusiasm about this collaboration and the integration of Ryght’s cutting-edge technology into their commitment to innovation. By harnessing the power of AI, the partnership aims to accelerate the identification of clinically qualified patients, leading to faster enrollment in clinical trials and unlocking new insights in the field of clinical research.
To learn more about Ryght’s platform and its capabilities, Simon Arkell will be presenting additional details at the DigiMed Showcase during the annual JPMorgan Healthcare Conference in San Francisco on January 9th, 2024. Furthermore, professionals in the life science industry can currently access a beta version of Ryght’s single-user platform, which is built on the same underlying technology.
[To share your insights with us, please write to [email protected]]
The source of the article is from the blog girabetim.com.br